StreetInsider.com News Articles

Form 4 Kardigan, Inc. For: Jun 17 Filed by: EDELMAN JOSEPH

Mon, 13 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260713/26763006.html

Leerink Starts Kardigan Inc (KARD) at Outperform

Mon, 13 Jul 2026 06:04:08 -0400

Leerink initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Outperform rating and a price target of $37.00.

For an analyst ratings summary and ratings history on Kardigan Inc click here. For more ratings news on Kardigan Inc click here.

Shares of Kardigan Inc closed at $24.64 yesterday.

TD Cowen Starts Kardigan Inc (KARD) at Buy

Mon, 13 Jul 2026 05:30:11 -0400

TD Cowen analyst Ritu Baral initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $46.00.

The analyst comments "We are initiating on KARD with a Buy and $46 PT. KARD's late-stage precision cardiology assets target the root causes of CVDs that have no approved treatments. We are bullish on lead asset Ph2b/3 dani' in gDCM; Ph2b/3 ATA in mod CAVS and Ph2b TLA in ASH represent 2 addt'l derisked shots on goal. We think 1H27 topline Ph2b data for all 3 assets will be positive, and support progression into Ph3."

For an analyst ratings summary

TD Cowen Starts Kardigan Inc (KARD) at Buy

Mon, 13 Jul 2026 05:30:11 -0400

TD Cowen analyst Ritu Baral initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $46.00.

For an analyst ratings summary

Jefferies Starts Kardigan Inc (KARD) at Buy

Mon, 13 Jul 2026 02:14:26 -0400

Jefferies analyst Dennis Ding initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $40.00.

The analyst comments: “We see value creating catalysts for KARD's three specialty cardiology programs in H1:27. At $2B cap, funded into 2028, and led by the ex-MYOK team, there's upside should even one of them work given our view each can be a blockbuster $1-3B drug and w/o the need for a large Phase III CVOT. Early data looks promising as biomarkers are trending in the right direction, and we need longer term data to confirm efficacy and also safety.

Jefferies Starts Kardigan Inc (KARD) at Buy

Mon, 13 Jul 2026 02:14:26 -0400

Jefferies analyst Dennis Ding initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $40.00.

JPMorgan Starts Kardigan Inc (KARD) at Overweight

Mon, 13 Jul 2026 02:11:55 -0400

JPMorgan analyst Anupam Rama initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Overweight rating and a price target of $51.00.

The analyst comments: “We are initiating coverage on Kardigan (KARD) with an Overweight rating and a December 2027 price target of $51. We see each of Kardigan’s mid-stage cardiovascular pipeline assets – danicamtiv (genetic dilated cardiomyopathy; DCM) / ataciguat (moderate calcific aortic valve stenosis; CAVS) / tonlamarsen (acute severe hypertension; ASH) – as having: 1) early de-risking proof-ofconcept data (though conservatively we model probability of success (POS) as <50% for each), 2) value-creating potential in the next ~6-12 month timeframe

JPMorgan Starts Kardigan Inc (KARD) at Overweight

Mon, 13 Jul 2026 02:11:55 -0400

JPMorgan analyst Anupam Rama initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Overweight rating and a price target of $51.00.

Form 4 Kardigan, Inc. For: Jun 22 Filed by: HRTG GPE, LLC

Wed, 24 Jun 2026 21:26:00 -0400

si-local-file:///var/storage/secattach/20260624/26686973.html

Form 3/A Kardigan, Inc. For: Jun 17 Filed by: HRTG GPE, LLC

Wed, 24 Jun 2026 21:15:00 -0400

si-local-file:///var/storage/secattach/20260624/26686967.html

Form 4 Kardigan, Inc. For: Jun 22 Filed by: BERNS PAUL L

Wed, 24 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260624/26685813.html

Form 4 Kardigan, Inc. For: Jun 22 Filed by: ARCH Venture Partners XIII, LLC

Wed, 24 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260624/26685785.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: HRTG GPE, LLC

Mon, 22 Jun 2026 21:57:00 -0400

si-local-file:///var/storage/secattach/20260622/26674678.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: ARCH Venture Partners XIII, LLC

Mon, 22 Jun 2026 19:40:00 -0400

si-local-file:///var/storage/secattach/20260622/26674514.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Pasternak Andy

Mon, 22 Jun 2026 19:30:00 -0400

si-local-file:///var/storage/secattach/20260622/26674503.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Meeker David P

Mon, 22 Jun 2026 19:28:00 -0400

si-local-file:///var/storage/secattach/20260622/26674501.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: BERNS PAUL L

Mon, 22 Jun 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260622/26674494.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Moriarty John B

Mon, 22 Jun 2026 19:23:00 -0400

si-local-file:///var/storage/secattach/20260622/26674492.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Jahn Brianne

Mon, 22 Jun 2026 19:20:00 -0400

si-local-file:///var/storage/secattach/20260622/26674486.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Popovits Kimberly J

Mon, 22 Jun 2026 19:19:00 -0400

si-local-file:///var/storage/secattach/20260622/26674483.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Walbert Timothy P

Mon, 22 Jun 2026 19:18:00 -0400

si-local-file:///var/storage/secattach/20260622/26674480.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: GIANAKAKOS ANASTASIOS

Mon, 22 Jun 2026 19:18:00 -0400

si-local-file:///var/storage/secattach/20260622/26674481.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Giordano Douglas E.

Mon, 22 Jun 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260622/26674477.html

Form 4 Kardigan, Inc. For: Jun 17 Filed by: Edelberg Jay

Mon, 22 Jun 2026 19:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26674474.html

Kardigan raises $460M in IPO on Nasdaq

Mon, 22 Jun 2026 17:03:10 -0400

Kardigan, Inc. (Nasdaq: KARD), a clinical-stage cardiovascular drug developer, closed its initial public offering of 28,750,000 shares of common stock at $16.00 per share, generating gross proceeds of $460 million before deducting underwriting discounts, commissions, and other expenses.

The total share count included the full exercise by underwriters of an option to purchase 3,750,000 additional shares. All shares were offered by Kardigan. The company's stock is listed on the Nasdaq Global Market under the ticker symbol "KARD."

J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC served as underwriters for the offering. The registration statements became effective